Lauriet

 
This research study is using an experimental medication called RO7105705. This therapy is being tested for its ability to breakdown neurofibrillary tangles caused by tau protein. If you have moderate Alzheimer’s disease (AD), you may be eligible for this study.
 
Age: 5085 years 
 
Duration: 3 years

 

Reimbursement: You will be compensated for your time and travel

Study procedures: Office visits, blood draws, oral medication, memory and thinking tests, MRI scans, PET scans or optional lumbar puncture (spinal tap)

 
If you are interested, please contact Samantha Kuney at skuney@bwh.harvard.edu or 617-732-7992.